Although SGLT2 inhibitors have demonstrated cardioprotective effects in both heart failure and non-heart failure patients—as shown in trials such as EMPA-REG OUTCOME and DAPA-HF—these benefits may not always be accompanied by significant changes in BNP levels, particularly in patients without overt cardiac dysfunction [37,38]. Here, SLC5A2 is linked to heart failure.